{
  "asset": "ERLEADA (apalutamide)",
  "query_terms": [
    "ERLEADA (apalutamide)",
    "apalutamide",
    "ERLEADA"
  ],
  "returned_unique": 20,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT04662580",
      "title": "A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "ARX517",
        "Apalutamide",
        "Abiraterone acetate",
        "Prednisone"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04662580"
    },
    {
      "nct_id": "NCT04325828",
      "title": "An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Salivary Gland Neoplasms"
      ],
      "lead_sponsor": "Janssen Pharmaceutical K.K.",
      "collaborators": [],
      "interventions": [
        "Apalutamide",
        "GnRH Agonist"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04325828"
    },
    {
      "nct_id": "NCT04108208",
      "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": null,
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Apalutamide",
        "Placebo",
        "Androgen-deprivation Therapy (ADT)"
      ],
      "last_update": "2025-12-18",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04108208"
    },
    {
      "nct_id": "NCT06019676",
      "title": "Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients, a Multicentre Prospective Observational Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": null,
      "conditions": [
        "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
      ],
      "lead_sponsor": "Royal Marsden NHS Foundation Trust",
      "collaborators": [
        "Janssen, LP"
      ],
      "interventions": [],
      "last_update": "2025-09-18",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06019676"
    },
    {
      "nct_id": "NCT02721979",
      "title": "A Phase 2 Study of Apalutamide in Active Surveillance Patients",
      "overall_status": "TERMINATED",
      "phase": "Phase 2",
      "conditions": [
        "Prostate Adenocarcinoma"
      ],
      "lead_sponsor": "University of Washington",
      "collaborators": [
        "Janssen Scientific Affairs, LLC",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Apalutamide",
        "Laboratory Biomarker Analysis",
        "Quality-of-Life Assessment",
        "Questionnaire Administration"
      ],
      "last_update": "2023-02-09",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02721979"
    },
    {
      "nct_id": "NCT03365297",
      "title": "Targeted Drug Intervention to Inhibit Cancer Progression in Men on Active Surveillance for Prostate Cancer. Therapeutics in Active Prostate Cancer Surveillance (TAPS01)",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Prostate Cancer"
      ],
      "lead_sponsor": "CCTU- Cancer Theme",
      "collaborators": [
        "Janssen-Cilag Ltd."
      ],
      "interventions": [
        "Apalutamide"
      ],
      "last_update": "2019-11-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03365297"
    },
    {
      "nct_id": "NCT02257736",
      "title": "A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "lead_sponsor": "Aragon Pharmaceuticals, Inc.",
      "collaborators": [],
      "interventions": [
        "Apalutamide",
        "Abiraterone acetate",
        "Prednisone",
        "Placebo"
      ],
      "last_update": "2025-12-22",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02257736"
    },
    {
      "nct_id": "NCT03436654",
      "title": "Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Prostate Cancer"
      ],
      "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
      "collaborators": [
        "Dana-Farber Cancer Institute"
      ],
      "interventions": [
        "Apalutamide",
        "Abiraterone Acetate",
        "Prednisone",
        "Radical Prostatectomy",
        "Extended Pelvic lymphadenectomy",
        "GnRH agonist/antagonist",
        "Stereotactic Body Radiation Therapy"
      ],
      "last_update": "2025-11-28",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03436654"
    },
    {
      "nct_id": "NCT04585932",
      "title": "Phase 2 Response Evaluation of Finite Systemic Therapy With Advanced Androgen Signaling Inhibition and Radiation Therapy for Oligorecurrent Prostate Cancer (RESTART)",
      "overall_status": "WITHDRAWN",
      "phase": "Phase 2",
      "conditions": [
        "Biochemically Recurrent Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Oligometastatic Prostate Carcinoma",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "lead_sponsor": "M.D. Anderson Cancer Center",
      "collaborators": [
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Apalutamide",
        "Degarelix",
        "Leuprolide Acetate",
        "Quality-of-Life Assessment",
        "Questionnaire Administration",
        "Radiation Therapy"
      ],
      "last_update": "2021-01-20",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04585932"
    },
    {
      "nct_id": "NCT04421222",
      "title": "A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "phase": "Phase 1",
      "conditions": [
        "Prostate Cancer"
      ],
      "lead_sponsor": "ESSA Pharmaceuticals",
      "collaborators": [],
      "interventions": [
        "EPI-7386 (QD)",
        "EPI-7386 (BID)",
        "Abiraterone acetate",
        "Apalutamide"
      ],
      "last_update": "2025-02-28",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04421222"
    }
  ]
}